Literature DB >> 29373210

Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study.

Chao Wu1, Juan Huang2, Wen-Bin Xu3, Yong-Jing Guan2, Hua-Wei Ling2, Jian-Qing Mi3, Hua Yan4.   

Abstract

RATIONALE AND
OBJECTIVES: This study aimed to measure apparent diffusion coefficient (ADC) in Chinese patients with newly diagnosed multiple myeloma by whole-body diffusion-weighted magnetic resonance imaging (WB-DWI MRI) and assess the diagnostic accuracy of ADC in the discrimination of deep response to induction chemotherapy.
MATERIALS AND METHODS: Seventeen patients underwent WB-DWI MRI before and after induction chemotherapy (week 20). DWI images and ADC maps were produced and 89 regions of interest were chosen. ADC percent changes were compared between deep (complete response or very good partial response) and non-deep responders (partial response, minimal response, stable disease, or progressive disease) as International Myeloma Working Group criteria. Diagnostic accuracy of ADC was calculated using specific cut offs. Predictive positive value of ADC was calculated to predict deep response to consolidation therapy.
RESULTS: Lesions reduced in size and number and signal intensity decreased in follow-up DWI, which did not differ between deep and non-deep responders. ADC percent changes were significantly higher in deep responders (36.79%) than in non-deep responders (11.50%) after induction therapy (P = .02) in per lesion analysis. ADC percent increases by 46.96%, 78.0% yielded specificity at 81.4%, 90.7% in discriminating deep response to induction therapy. Predictive positive value predicting deep response to consolidation therapy was 60.5% by using ADC cutoff >1.00 × 10-3 mm2/s at week 20.
CONCLUSIONS: ADC from WB-DWI MRI increased remarkably in patients who achieved deep response at the end of induction chemotherapy, which represented a confirmatory diagnostic tool to discriminate deep response to induction therapy for patients with multiple myeloma. ADC may have a potential to predict deep response to consolidation therapy.
Copyright © 2018 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Multiple myeloma; apparent diffusion coefficient; depth of response; whole-body diffusion-weighted MRI

Mesh:

Year:  2018        PMID: 29373210     DOI: 10.1016/j.acra.2017.12.008

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  7 in total

1.  Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis.

Authors:  Pooya Torkian; Bahar Mansoori; Jens Hillengass; Javid Azadbakht; Sina Rashedi; Sarah S Lee; Behrang Amini; Pietro Andrea Bonaffini; Majid Chalian
Journal:  Skeletal Radiol       Date:  2022-07-26       Impact factor: 2.128

2.  Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis.

Authors:  Kaiwen Wang; Elsa Lee; Shedrack Kenis; Simon Hallam; Athar Haroon; Simon Wan; Neil Rabin; Antonio Rojas-Garcia; Anwar Padhani; Sola Adeleke
Journal:  Eur Radiol       Date:  2022-01-14       Impact factor: 7.034

Review 3.  Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting.

Authors:  Giulia Ferrarazzo; Silvia Chiola; Selene Capitanio; Maria Isabella Donegani; Alberto Miceli; Stefano Raffa; Alberto Stefano Tagliafico; Silvia Morbelli; Matteo Bauckneht
Journal:  Diagnostics (Basel)       Date:  2021-02-03

4.  Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma.

Authors:  Bei Zhang; Bingyang Bian; Zhiwei Zhao; Fang Lin; Zining Zhu; Mingwu Lou
Journal:  BMC Med Imaging       Date:  2021-06-08       Impact factor: 1.930

5.  Whole-body diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient values as prognostic factors in multiple myeloma.

Authors:  Dan Costachescu; Ioana Ionita; Ema-Cristina Borsi; Ovidiu Potre; Cristina Potre; Dan-Bogdan Navolan; Alexandru Blidisel; Hortensia Ionita; Adelina Erimescu; Gheorghe Nicusor Pop; Daniel Claudiu Malita
Journal:  Exp Ther Med       Date:  2021-06-03       Impact factor: 2.447

Review 6.  Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.

Authors:  Bastien Jamet; Elena Zamagni; Cristina Nanni; Clément Bailly; Thomas Carlier; Cyrille Touzeau; Anne-Victoire Michaud; Philippe Moreau; Caroline Bodet-Milin; Françoise Kraeber-Bodere
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

Review 7.  Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.

Authors:  Frederic E Lecouvet; Marie-Christiane Vekemans; Thomas Van Den Berghe; Koenraad Verstraete; Thomas Kirchgesner; Souad Acid; Jacques Malghem; Joris Wuts; Jens Hillengass; Vincent Vandecaveye; François Jamar; Olivier Gheysens; Bruno C Vande Berg
Journal:  Skeletal Radiol       Date:  2021-08-07       Impact factor: 2.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.